NVZMY Quote, Financials, Valuation and Earnings

Flexible Solutions International has a net margin of 17.26% compared to Novonesis (Novozymes) B's net margin of -3.72%. Novonesis (Novozymes) B's return on equity of 6.56% beat Flexible Solutions International's return on equity of 5.71%.

Novonesis (Novozymes) B has a consensus price target of --, signalling downside risk potential of --. On the other hand Flexible Solutions International has an analysts' consensus of $9.00 which suggests that it could grow by 106.42%. Given that Flexible Solutions International has higher upside potential than Novonesis (Novozymes) B, analysts believe Flexible Solutions International is more attractive than Novonesis (Novozymes) B.

Novonesis (Novozymes) B has a beta of 0.917, which suggesting that the stock is 8.343% less volatile than S&P 500. In comparison Flexible Solutions International has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.91%.

Novonesis (Novozymes) B has a quarterly dividend of $0.61 per share corresponding to a yield of 1.62%. Flexible Solutions International offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Novonesis (Novozymes) B pays 81.69% of its earnings as a dividend. Flexible Solutions International pays out 41.31% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novonesis (Novozymes) B quarterly revenues are $1.1B, which are larger than Flexible Solutions International quarterly revenues of $7.5M. Novonesis (Novozymes) B's net income of $195.7M is higher than Flexible Solutions International's net income of -$277.7K. Notably, Novonesis (Novozymes) B's price-to-earnings ratio is 65.02x while Flexible Solutions International's PE ratio is 24.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novonesis (Novozymes) B is 6.54x versus 1.52x for Flexible Solutions International. Usually stocks with elevated PS ratios are considered overvalued.

Grupo Simec SAB de CV has a net margin of 17.26% compared to Novonesis (Novozymes) B's net margin of 16.76%. Novonesis (Novozymes) B's return on equity of 6.56% beat Grupo Simec SAB de CV's return on equity of 18.65%.

Novonesis (Novozymes) B has a consensus price target of --, signalling downside risk potential of --. On the other hand Grupo Simec SAB de CV has an analysts' consensus of -- which suggests that it could fall by -57.62%. Given that Grupo Simec SAB de CV has higher upside potential than Novonesis (Novozymes) B, analysts believe Grupo Simec SAB de CV is more attractive than Novonesis (Novozymes) B.

Novonesis (Novozymes) B has a beta of 0.917, which suggesting that the stock is 8.343% less volatile than S&P 500. In comparison Grupo Simec SAB de CV has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.753%.

Novonesis (Novozymes) B has a quarterly dividend of $0.61 per share corresponding to a yield of 1.62%. Grupo Simec SAB de CV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novonesis (Novozymes) B pays 81.69% of its earnings as a dividend. Grupo Simec SAB de CV pays out -- of its earnings as a dividend. Novonesis (Novozymes) B's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novonesis (Novozymes) B quarterly revenues are $1.1B, which are larger than Grupo Simec SAB de CV quarterly revenues of $380.6M. Novonesis (Novozymes) B's net income of $195.7M is higher than Grupo Simec SAB de CV's net income of $63.8M. Notably, Novonesis (Novozymes) B's price-to-earnings ratio is 65.02x while Grupo Simec SAB de CV's PE ratio is 9.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novonesis (Novozymes) B is 6.54x versus 2.56x for Grupo Simec SAB de CV. Usually stocks with elevated PS ratios are considered overvalued.

SP Group AS has a net margin of 17.26% compared to Novonesis (Novozymes) B's net margin of 9.99%. Novonesis (Novozymes) B's return on equity of 6.56% beat SP Group AS's return on equity of 16.6%.

Novonesis (Novozymes) B has a consensus price target of --, signalling downside risk potential of --. On the other hand SP Group AS has an analysts' consensus of -- which suggests that it could fall by --. Given that Novonesis (Novozymes) B has higher upside potential than SP Group AS, analysts believe Novonesis (Novozymes) B is more attractive than SP Group AS.

Novonesis (Novozymes) B has a beta of 0.917, which suggesting that the stock is 8.343% less volatile than S&P 500. In comparison SP Group AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novonesis (Novozymes) B has a quarterly dividend of $0.61 per share corresponding to a yield of 1.62%. SP Group AS offers a yield of 2.05% to investors and pays a quarterly dividend of $0.61 per share. Novonesis (Novozymes) B pays 81.69% of its earnings as a dividend. SP Group AS pays out 13.93% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novonesis (Novozymes) B quarterly revenues are $1.1B, which are larger than SP Group AS quarterly revenues of $110.9M. Novonesis (Novozymes) B's net income of $195.7M is higher than SP Group AS's net income of $11.1M. Notably, Novonesis (Novozymes) B's price-to-earnings ratio is 65.02x while SP Group AS's PE ratio is 9.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novonesis (Novozymes) B is 6.54x versus 0.84x for SP Group AS. Usually stocks with elevated PS ratios are considered overvalued.

Sustainable Projects Group has a net margin of 17.26% compared to Novonesis (Novozymes) B's net margin of --. Novonesis (Novozymes) B's return on equity of 6.56% beat Sustainable Projects Group's return on equity of --.

Novonesis (Novozymes) B has a consensus price target of --, signalling downside risk potential of --. On the other hand Sustainable Projects Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Novonesis (Novozymes) B has higher upside potential than Sustainable Projects Group, analysts believe Novonesis (Novozymes) B is more attractive than Sustainable Projects Group.

Novonesis (Novozymes) B has a beta of 0.917, which suggesting that the stock is 8.343% less volatile than S&P 500. In comparison Sustainable Projects Group has a beta of -5.343, suggesting its less volatile than the S&P 500 by 634.347%.

Novonesis (Novozymes) B has a quarterly dividend of $0.61 per share corresponding to a yield of 1.62%. Sustainable Projects Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novonesis (Novozymes) B pays 81.69% of its earnings as a dividend. Sustainable Projects Group pays out -- of its earnings as a dividend. Novonesis (Novozymes) B's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novonesis (Novozymes) B quarterly revenues are $1.1B, which are larger than Sustainable Projects Group quarterly revenues of --. Novonesis (Novozymes) B's net income of $195.7M is higher than Sustainable Projects Group's net income of -$932.6K. Notably, Novonesis (Novozymes) B's price-to-earnings ratio is 65.02x while Sustainable Projects Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novonesis (Novozymes) B is 6.54x versus 13,224.49x for Sustainable Projects Group. Usually stocks with elevated PS ratios are considered overvalued.